Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vertex announces FDA approval of Alyftrek
Vertex Pharmaceuticals (VRTX) announced that the U.S. Food and Drug Administration has approved Alyftrek, a once-daily next-in-class triple ...
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.
Vertex Pharmaceuticals宣布ALYFTREK获得FDA批准
这一消息直接来自Vertex Pharmaceuticals Incorporated，报告的签署人是公司执行副总裁兼首席法务官Jonathan Biller。FDA对ALYFTREK的批准是Vertex Pharmaceuticals的一个重要进展，可能会加强公司在囊性纤维化治疗领域的产品组合。
Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...
来自MSN1 天
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...
Le Lézard1 天
Vertex Announces US FDA Approval of ALYFTREKtm, a Once-Daily Next-in-Class CFTR Modulator ...
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple ...
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
Cystic Fibrosis Foundation1 天
FDA Approves New, Once-a-Day CFTR Modulator for People With CF
A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations ...
Yahoo Finance2 天
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals lost more than $15 billion in value Thursday as new data on its closely watched ...
The Boston Globe2 天
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall Thursday. Vertex, based in ...